Keep recurrent C. diff infection from coming back with
one dose of REBYOTA®

Flowers on a vine

What is REBYOTA?

One dose one visit

REBYOTA (“REE-bye-oh-ta”) is the first and only single-dose, FDA-approved microbiome-based therapy to keep recurrrent C. diff infection from coming back, after you’ve taken antibiotics.1

There are multiple location options for administration of REBYOTA

REBYOTA can be administered in your doctor’s office or right in your home—in one dose, one visit. Please speak with your doctor about which option is best for you and they will help get you started.

Doctor icon

REBYOTA administration 
in your doctor’s office

REBYOTA can be administered right in your doctor’s office once you’ve completed your course of antibiotics. After administration, there is a 15-minute wait period, after which you can go home.

House icon


If you are unable to receive REBYOTA in your doctor’s office, you may benefit from the option of administration via home health in the comfort of your home.


REBYOTA patient stories

Watch patients tell their stories of how REBYOTA helped 
keep recurrent C. diff infection from coming back.

Heather Large

It has been six months since REBYOTA. I have not had another recurrence.

– Heather, Actual REBYOTA Patient

Most common side effects may include stomach pain, 
diarrhea, bloating, gas, and nausea.1
For more information, please talk to your doctor and see full Prescribing Information. 
Heather was compensated for her time. Individual results may vary.

REBYOTA support and resources

Access REBYOTA support information to learn more about recurrent C. diff infection, get caregiver tips, and to download a diary to keep track of your journey.

REBYOTA Support Resources
REBYOTA Support Resources
Flowers on a vine Flowers on a vine

REBYOTA is the first and only single-dose, FDA-approved microbiome-based therapy to keep 
recurrent C. diff infection from coming back, after you’ve already taken antibiotics.1

Sign up for more information

Receive additional information and resources to help you through your C. diff infection journey.

What’s your experience with C. diff infection?*(Required)

*Required field.


  1. REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.

Please see Important Safety Information and full Prescribing Information


REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.

Important Safety Information

  • You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
  • You should report to your doctor any infection you think you may have acquired after administration.
  • REBYOTA may contain food allergens.
  • Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
  • REBYOTA has not been studied in patients below 18 years of age.
  • Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-1088.

Please click to see the full Prescribing Information.

You are leaving

The link you have selected will direct you to a site or resource outside of our website.
Thank you.